FI934145A0 - Omformade monoklonala antikroppar mot en immunoglobulinisotyp - Google Patents
Omformade monoklonala antikroppar mot en immunoglobulinisotypInfo
- Publication number
- FI934145A0 FI934145A0 FI934145A FI934145A FI934145A0 FI 934145 A0 FI934145 A0 FI 934145A0 FI 934145 A FI934145 A FI 934145A FI 934145 A FI934145 A FI 934145A FI 934145 A0 FI934145 A0 FI 934145A0
- Authority
- FI
- Finland
- Prior art keywords
- omformade
- immunoglobulinisotyp
- monoclonal
- mot
- antikroppar mot
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929220228A GB9220228D0 (en) | 1992-09-24 | 1992-09-24 | Reshaped monoclonal antibodies against an immunologlobulin isotype |
GB9220228 | 1992-09-24 | ||
US95280292A | 1992-09-25 | 1992-09-25 | |
US95280292 | 1992-09-25 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI934145A0 true FI934145A0 (fi) | 1993-09-22 |
FI934145L FI934145L (fi) | 1994-03-25 |
FI114550B FI114550B (fi) | 2004-11-15 |
Family
ID=26301683
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI934145A FI114550B (fi) | 1992-09-24 | 1993-09-22 | Menetelmä immunoglobuliini-isotyyppiä vastaan suunnattujen uudelleenmuotoiltujen monoklonaalisten vasta-aineiden valmistamiseksi |
FI20040696A FI115838B (fi) | 1992-09-24 | 2004-05-19 | Ihmisen uusimuotoisten monoklonaalisen, IgE:lle spesifisen vasta-aineen käyttö IgE:n kvalitatiiviseen tai kvantitatiiviseen määrittämiseen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI20040696A FI115838B (fi) | 1992-09-24 | 2004-05-19 | Ihmisen uusimuotoisten monoklonaalisen, IgE:lle spesifisen vasta-aineen käyttö IgE:n kvalitatiiviseen tai kvantitatiiviseen määrittämiseen |
Country Status (18)
Country | Link |
---|---|
EP (2) | EP1452542A3 (fi) |
JP (2) | JP3636737B2 (fi) |
KR (1) | KR100298608B1 (fi) |
CN (2) | CN1078250C (fi) |
AT (1) | ATE264388T1 (fi) |
AU (1) | AU675449B2 (fi) |
CA (1) | CA2106719C (fi) |
CY (1) | CY2583B2 (fi) |
DE (1) | DE69333484T2 (fi) |
DK (1) | DK0589840T3 (fi) |
ES (1) | ES2219640T3 (fi) |
FI (2) | FI114550B (fi) |
HK (1) | HK1056182A1 (fi) |
IL (2) | IL107049A (fi) |
MX (1) | MX9305920A (fi) |
NO (1) | NO318210B1 (fi) |
NZ (1) | NZ248743A (fi) |
PT (1) | PT589840E (fi) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
ZA966075B (en) * | 1995-07-27 | 1998-01-19 | Genentech Inc | Protein formulation. |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
AU7156996A (en) * | 1995-09-13 | 1997-04-01 | Genentech Inc. | Methods for treatment of interstitial cystitis |
US6127524A (en) * | 1996-10-18 | 2000-10-03 | Dade Behring Inc. | Binding molecules and computer-based methods of increasing the binding affinity thereof |
AU2103699A (en) * | 1998-01-29 | 1999-08-16 | Tse Wen Chang | Treating atopic dermatitis with ige antagonists |
US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
EP1900753B1 (en) | 2002-11-08 | 2017-08-09 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
AU2003283137B8 (en) * | 2002-11-08 | 2010-07-29 | Ablynx N.V. | Camelidae antibodies against immunoglobulin E and use thereof for the treatment of allergic disorders |
US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
AU2004209638B2 (en) * | 2003-02-01 | 2011-02-03 | Tanox, Inc. | High affinity anti-human IgE antibodies |
AU2004315197B2 (en) * | 2004-02-02 | 2009-06-04 | Tanox, Inc. | Identification of novel IgE epitopes |
JP5823867B2 (ja) | 2008-10-29 | 2015-11-25 | アブリンクス エン.ヴェー. | 単一ドメイン抗原結合分子の製剤 |
KR20110079693A (ko) | 2008-10-29 | 2011-07-07 | 와이어쓰 엘엘씨 | 단일 도메인 항원 결합 분자의 정제 방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3853636T3 (de) * | 1987-12-31 | 1999-04-08 | Tanox Biosystems, Inc., Houston, Tex. | Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden. |
US5104604A (en) * | 1989-10-05 | 1992-04-14 | Dexter Electronic Materials Div. Of Dexter Corp. | Flame retardant epoxy molding compound, method and encapsulated device method of encapsulating a semiconductor device with a flame retardant epoxy molding compound |
JP2988635B2 (ja) * | 1990-09-18 | 1999-12-13 | 塩野義製薬株式会社 | ヒトIgEに対するモノクローナル抗体 |
WO1992017207A1 (en) * | 1991-03-26 | 1992-10-15 | Tanox Biosystems, Inc. | MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS |
AU2498192A (en) * | 1991-08-14 | 1993-03-16 | Genentech Inc. | Immunoglobulin variants for specific fc epsilon receptors |
-
1993
- 1993-09-15 DE DE69333484T patent/DE69333484T2/de not_active Expired - Lifetime
- 1993-09-15 AT AT93810653T patent/ATE264388T1/de not_active IP Right Cessation
- 1993-09-15 ES ES93810653T patent/ES2219640T3/es not_active Expired - Lifetime
- 1993-09-15 PT PT93810653T patent/PT589840E/pt unknown
- 1993-09-15 EP EP04008222A patent/EP1452542A3/en not_active Withdrawn
- 1993-09-15 DK DK93810653T patent/DK0589840T3/da active
- 1993-09-15 EP EP93810653A patent/EP0589840B1/en not_active Expired - Lifetime
- 1993-09-20 AU AU47488/93A patent/AU675449B2/en not_active Ceased
- 1993-09-20 IL IL107049A patent/IL107049A/en not_active IP Right Cessation
- 1993-09-20 IL IL173988A patent/IL173988A0/en unknown
- 1993-09-22 FI FI934145A patent/FI114550B/fi active IP Right Grant
- 1993-09-22 CA CA002106719A patent/CA2106719C/en not_active Expired - Fee Related
- 1993-09-22 NZ NZ248743A patent/NZ248743A/en not_active IP Right Cessation
- 1993-09-23 NO NO19933394A patent/NO318210B1/no not_active IP Right Cessation
- 1993-09-24 KR KR1019930019631A patent/KR100298608B1/ko not_active IP Right Cessation
- 1993-09-24 MX MX9305920A patent/MX9305920A/es not_active IP Right Cessation
- 1993-09-24 JP JP23818093A patent/JP3636737B2/ja not_active Expired - Fee Related
- 1993-09-24 CN CN93119845A patent/CN1078250C/zh not_active Expired - Fee Related
-
2001
- 2001-12-14 CN CNB011436433A patent/CN1254487C/zh not_active Expired - Fee Related
-
2003
- 2003-11-21 HK HK03108492A patent/HK1056182A1/xx not_active IP Right Cessation
-
2004
- 2004-05-19 FI FI20040696A patent/FI115838B/fi active IP Right Grant
- 2004-07-07 JP JP2004201096A patent/JP3718214B2/ja not_active Expired - Fee Related
-
2005
- 2005-09-08 CY CY0500048A patent/CY2583B2/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI934145A0 (fi) | Omformade monoklonala antikroppar mot en immunoglobulinisotyp | |
NO2017040I1 (no) | Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC | |
NO991591L (no) | Rekonstituert human anti-HM1.24 antistoff | |
FI951488L (fi) | Ihmisen immuunikatoviruksen vastaiset ihmisen neutraloivat monoklonaaliset vasta-aineet | |
DK0758904T3 (da) | Fremgangsmåder og sammensætninger til behandling af glomerulonephritis | |
EP0675734A4 (en) | MONOCLONAL ALLERGEN-SPECIFIC IgA ANTIBODIES AND RELATED PRODUCTS FOR THE TREATMENT OF ALLERGIES. | |
DK0986577T3 (da) | Opsonisk og beskyttende monoklonale og kimære antistoffer specifikke for lipoteichoicsyre af grampositive bakterier | |
ATE348113T1 (de) | Rekombinanter anti-cd4 antikörper zur menschlichen behandlung | |
ATE347565T1 (de) | Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien | |
ZA946767B (en) | Monocional antibodies having property of causing apoptosis. | |
DE59209129D1 (de) | Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression | |
ATE166230T1 (de) | Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock | |
ATE151078T1 (de) | Verfahren und zwischenprodukte synthetischer antikörperderivate | |
MX9301858A (es) | Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv. | |
ATE1443T1 (de) | Mittel zur behandlung allergischer reaktionen. | |
ATE199321T1 (de) | Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen. | |
BR9304004A (pt) | Método de tratamento de arrozal | |
DE69418931D1 (de) | Verwendung von VIP und deren Analogen und Fragmenten zur Behandlung von neurodegenerativen Krankheiten | |
DE3786173D1 (de) | Menschlicher monoklonaler antikoerper und arzneimittel zur prophylaxe und behandlung von infektioesen krankheiten. | |
RU95110653A (ru) | Средство, стимулирующее в эксперименте синтез иммуноглобулинов | |
RU93035807A (ru) | Способ лечения юношеского эпифизиолиса | |
DE59203041D1 (de) | Vorrichtung für die Wärmebehandlung und den Transport von Substraten. | |
SE9404491D0 (sv) | Process for the production of human monoclonal antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or assigment of application |
Owner name: NOVARTIS AG |
|
FG | Patent granted |
Ref document number: 114550 Country of ref document: FI |